Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA/device industry meeting

This article was originally published in The Gray Sheet

Executive Summary

FDA's Center for Devices and Radiological Health meets with device industry representatives to discuss the center's product review program. Among the topics addressed at the Jan. 13 session were steps to reduce the backlog of pending 510(k) and premarket approval applications. A report on the backlog was presented by FDA. The meeting was the fourth FDA/industry exchange meeting that has been held since June ("The Gray Sheet" Nov. 30, p. 8). FDAers at the recent session included CDRH Acting Director Elizabeth Jacobson and Office of Device Evaluation Acting Director Alan Andersen. Industry reps included officials from the Health Industry Manufacturers Association, the National Electrical Manufacturers Association, Johnson & Johnson, Baxter, Siemens and General Electric....

Latest Headlines
See All
UsernamePublicRestriction

Register

MT000080

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel